Boothbay Fund Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Boothbay Fund Management’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.04M	Sell	600,716 -11,444	-2%	-$38.8K	0.03%	609
2025 Q4	$1.74M	Sell	612,160 -233,231	-28%	-$602K	0.03%	604
2025 Q3	$2.23M	Hold	845,391	–	–	0.03%	540
2025 Q2	$1.9M	Sell	845,391 -97	-0%	-$214	0.04%	517
2025 Q1	$1.81M	Buy	845,488 +300	+0%	+$692	0.05%	451
2024 Q4	$2.05M	Buy	845,188 +16,857	+2%	+$40.1K	0.05%	441
2024 Q3	$2.02M	Buy	828,331 +3,333	+0.4%	+$8.13K	0.05%	515
2024 Q2	$2.12M	Buy	824,998 +135,249	+20%	+$321K	0.05%	477
2024 Q1	$2.01M	Buy	689,749 +164,748	+31%	+$461K	0.04%	511
2023 Q4	$1.21M	Buy	+525,001	New	+$1.12M	0.03%	669
2020 Q3	–	Sell	-30,963	Closed	-$109K	–	1162
2020 Q2	$109K	Sell	30,963 -6,110	-16%	-$20.5K	0.01%	874
2020 Q1	$113K	Buy	+37,073	New	+$162K	0.01%	716

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Aquamarine Financial George Town $1.37B AUM

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $102M AUM

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

RWM

Ritholtz Wealth Management New York $5.76B AUM 24.57% 1-Year Est. Return

Boothbay Fund Management's ORMP Position: Q1 2026 in Review

Boothbay Fund Management reduced its Oramed Pharmaceuticals (ORMP) stake by 1.9% in Q1 2026, selling an estimated $38.8K and leaving 600,716 shares worth $2.04M. The position accounts for 0.03% of the portfolio, ranked #609.

Boothbay Fund Management first reported a position in ORMP in Q1 2020 and has held it in 12 quarters since. The position peaked at $2.23M in Q3 2025. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

Boothbay Fund Management held 600,716 shares of Oramed Pharmaceuticals worth $2.04M as of Q1 2026.
Boothbay Fund Management sold 11,444 Oramed Pharmaceuticals shares in Q1 2026, an estimated $38.8K.
Oramed Pharmaceuticals made up 0.03% of Boothbay Fund Management's portfolio in Q1 2026, its #609 holding.
Boothbay Fund Management first reported a position in Oramed Pharmaceuticals in Q1 2020 and has held it in 12 quarters since.
Boothbay Fund Management's Oramed Pharmaceuticals position peaked at $2.23M in Q3 2025.
64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.